🇺🇸 FDA
Pipeline program

sepofarsen

PQ-110-003

Phase 3 small_molecule active

Quick answer

sepofarsen for Leber Congenital Amaurosis 10 is a Phase 3 program (small_molecule) at ProQR Therapeutics N.V. with 2 ClinicalTrials.gov record(s).

Program details

Company
ProQR Therapeutics N.V.
Indication
Leber Congenital Amaurosis 10
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials